TFAP2A
Transcription factor AP-2-alpha
Also known as: AP-2, AP-2alpha, AP2A_HUMAN, AP2TF, TFAP2
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P05549
- Gene
- TFAP2A
- Ensembl
- ENSG00000137203
- Chromosome
- 6
- Canonical length
- 437 aa
- Protein class
- Disease related genes, Human disease related genes, Predicted intracellular proteins, Transcription factors
- Subcellular location
- Nucleoplasm
- Quaternary structure
- Homodimer
OverviewNCBI Gene
The protein encoded by this gene is a transcription factor that binds the consensus sequence 5'-GCCNNNGGC-3'. The encoded protein functions as either a homodimer or as a heterodimer with similar family members. This protein activates the transcription of some genes while inhibiting the transcription of others. Defects in this gene are a cause of branchiooculofacial syndrome (BOFS). Three transcript variants encoding different isoforms have been found for this gene.[provided by RefSeq, Dec 2009]
Canonical amino-acid sequenceUniProt
437 residues, UniProt reviewed canonical sequence.
>P05549|TFAP2A
1 MLWKLTDNIK YEDCEDRHDG TSNGTARLPQ LGTVGQSPYT SAPPLSHTPN ADFQPPYFPP
61 PYQPIYPQSQ DPYSHVNDPY SLNPLHAQPQ PQHPGWPGQR QSQESGLLHT HRGLPHQLSG
121 LDPRRDYRRH EDLLHGPHAL SSGLGDLSIH SLPHAIEEVP HVEDPGINIP DQTVIKKGPV
181 SLSKSNSNAV SAIPINKDNL FGGVVNPNEV FCSVPGRLSL LSSTSKYKVT VAEVQRRLSP
241 PECLNASLLG GVLRRAKSKN GGRSLREKLD KIGLNLPAGR RKAANVTLLT SLVEGEAVHL
301 ARDFGYVCET EFPAKAVAEF LNRQHSDPNE QVTRKNMLLA TKQICKEFTD LLAQDRSPLG
361 NSRPNPILEP GIQSCLTHFN LISHGFGSPA VCAAVTALQN YLTEALKAMD KMYLSNNPNS
421 HTDNNAKSSD KEEKHRKLocalizationUniProt · AlphaFold · HPA
Whether an antibody against TFAP2A can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.53
- Highest tissue expression
- 63 nTPM
Expression across tissuesHPA
Tissue
- skin: 63 nTPM
- breast: 31 nTPM
- placenta: 28 nTPM
- esophagus: 26 nTPM
- salivary gland: 22 nTPM
- epididymis: 21 nTPM
Single-cell type
- syncytiotrophoblasts: 884 nCPM
- melanocytes: 388 nCPM
- extravillous trophoblasts: 369 nCPM
- cytotrophoblasts: 345 nCPM
- migrating cytotrophoblasts: 324 nCPM
- retinal amacrine cells: 176 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- cerebellum: 9.3 nTPM
- medulla oblongata: 7.2 nTPM
- pons: 4.9 nTPM
- midbrain: 3.3 nTPM
- white matter: 1.7 nTPM
- cerebral cortex: 1.5 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about TFAP2A.
Disease | AllUniProt
Conditions TFAP2A is implicated in, by any mechanism.
- Branchiooculofacial syndrome (BOFS) MIM:113620
Disease | GeneticClinVar
52 pathogenic / likely-pathogenic of 318 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Branchiooculofacial syndrome
- Inborn genetic diseases
- TFAP2A-related disorder
- Chromatinopathy
- 13 conditions
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.26
- gnomAD pLI
- 0.99
- gnomAD missense Z
- 2.59
- DepMap mean gene effect
- -0.07
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- bone morphogenesis
- cellular response to iron ion
- embryonic cranial skeleton morphogenesis
- embryonic forelimb morphogenesis
- eyelid development in camera-type eye
- inner ear morphogenesis
- kidney development
- negative regulation of apoptotic process
- negative regulation of cell population proliferation
- negative regulation of DNA-templated transcription
- negative regulation of reactive oxygen species metabolic process
- negative regulation of transcription by competitive promoter binding
- negative regulation of transcription by RNA polymerase II
- nervous system development
- oculomotor nerve formation
- optic vesicle morphogenesis
- positive regulation of bone mineralization
- positive regulation of DNA-templated transcription
- positive regulation of gene expression
- positive regulation of neuron apoptotic process
- positive regulation of tooth mineralization
- positive regulation of transcription by RNA polymerase II
- regulation of cell differentiation
- regulation of cell population proliferation
- retina layer formation
- roof of mouth development
- sensory perception of sound
- skeletal system development
- trigeminal nerve development
- optic cup structural organization
Molecular functions
- chromatin binding
- DNA binding
- DNA-binding transcription activator activity, RNA polymerase II-specific
- DNA-binding transcription factor activity, RNA polymerase II-specific
- DNA-binding transcription repressor activity, RNA polymerase II-specific
- identical protein binding
- RNA polymerase II cis-regulatory region sequence-specific DNA binding
- RNA polymerase II transcription regulatory region sequence-specific DNA binding
- sequence-specific DNA binding
- sequence-specific double-stranded DNA binding
- transcription cis-regulatory region binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Transcription factor AP-2
- Transcription factor AP-2, C-terminal
- Transcription factor AP-2
- Transcription factor AP-2 alpha, N-terminal
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of TFAP2A in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads TFAP2A as an antibody target. Whether an autoantibody or antibody against TFAP2A could matter depends on whether native TFAP2A is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
TFAP2A is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label TFAP2A as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...